Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells
Krishnan K. Mahadevan, Kathleen M. McAndrews, Valerie S. LeBleu, et al.
Cancer Cell (2023) Vol. 41, Iss. 9, pp. 1606-1620.e8
Open Access | Times Cited: 99

Showing 1-25 of 99 citing articles:

Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 67
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Míriam Molina‐Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 46
Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
Jiawen Cui, Yao Li, Yang Yang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116203-116203
Open Access | Times Cited: 36
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36
Cold and hot tumors: from molecular mechanisms to targeted therapy
Bo Wu, Bo Zhang, Bowen Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 34
Current and future immunotherapeutic approaches in pancreatic cancer treatment
Pooya Farhangnia, Hossein Khorramdelazad, Hamid Nickho, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 29
Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept
Wenyu Luo, Ti Wen, Xiujuan Qu
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 22
Combinatorial strategies to target RAS-driven cancers
Naiara Perurena, Lisa Situ, Karen Cichowski
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 316-337
Closed Access | Times Cited: 22
AGER-dependent macropinocytosis drives resistance to KRAS-G12D–targeted therapy in advanced pancreatic cancer
Changfeng Li, Yuanda Liu, Chang Liu, et al.
Science Translational Medicine (2025) Vol. 17, Iss. 783
Closed Access | Times Cited: 2
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
Daoyan Wei, Liang Wang, Xiangsheng Zuo, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 4, pp. 655-662
Open Access | Times Cited: 35
Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells
Krishnan K. Mahadevan, Valerie S. LeBleu, Elena V. Ramirez, et al.
Developmental Cell (2023) Vol. 58, Iss. 17, pp. 1562-1577.e8
Open Access | Times Cited: 31
Recent advances in drug delivery and targeting for the treatment of pancreatic cancer
Nilkamal Pramanik, Aditya K. Gupta, Yashwardhan Ghanwatkar, et al.
Journal of Controlled Release (2024) Vol. 366, pp. 231-260
Closed Access | Times Cited: 13
Next-generation therapies for pancreatic cancer
Conor Buckley, Eileen M. O’Reilly
Expert Review of Gastroenterology & Hepatology (2024) Vol. 18, Iss. 1-3, pp. 55-72
Open Access | Times Cited: 12
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Leonard J. Ash, Ottavia Busia-Bourdain, Daniel Okpattah, et al.
Current Oncology (2024) Vol. 31, Iss. 4, pp. 2024-2046
Open Access | Times Cited: 10
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer
Haniel A. Araújo, Ximo Pechuan-Jorge, Teng Zhou, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2183-2208
Closed Access | Times Cited: 10
Precision treatment of pancreatic ductal adenocarcinoma
Hongyun Wei, He Ren
Cancer Letters (2024) Vol. 585, pp. 216636-216636
Closed Access | Times Cited: 8
Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy
Jie Mei, Xingjian Liu, Huixiang Tian, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 4
Open Access | Times Cited: 8
Overcoming therapy resistance in pancreatic cancer: New insights and future directions
Margarita Espona‐Fiedler, Cédric Patthey, Stina Lindblad, et al.
Biochemical Pharmacology (2024) Vol. 229, pp. 116492-116492
Open Access | Times Cited: 8
Genetic Signature of Human Pancreatic Cancer and Personalized Targeting
Stephan J. Reshkin, Rosa Angela Cardone, Tomas Koltai
Cells (2024) Vol. 13, Iss. 7, pp. 602-602
Open Access | Times Cited: 7
Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application
Rui Zheng, Xiaobin Liu, Yufu Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection
Elena Brozos-Vázquez, Marta Toledano‐Fonseca, Nicolás Costa‐Fraga, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102719-102719
Open Access | Times Cited: 6
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment
Douglas Hanahan, Olivier Michielin, Mikaël J. Pittet
Nature reviews. Cancer (2024)
Closed Access | Times Cited: 6
Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian
Viviana Cortiana, Rabab Hunaid Abbas, Harshal Chorya, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2329-2329
Open Access | Times Cited: 5
Macroautophagy/autophagy promotes resistance to KRASG12D-targeted therapy through glutathione synthesis
Leng Han, Lingjun Meng, Jiao Liu, et al.
Cancer Letters (2024) Vol. 604, pp. 217258-217258
Open Access | Times Cited: 5
Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
Tuan Hoang, Erica S. Tsang
Journal of Gastrointestinal Cancer (2025) Vol. 56, Iss. 1
Closed Access
Page 1 - Next Page

Scroll to top